Cilostazol induces PGI2 production via activation of the downstream epac-1/rap1 signaling cascade to increase intracellular calcium by PLCε and to activate p44/42 MAPK in human aortic endothelial cells

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Hashimoto, Ayako ^a   Tanaka, Michinori ^a   Takeda, Satoshi ^a   Ito, Hideki ^a   Nagano, Keisuke ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 AMINOETHOXYDIPHENYLBORANE; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; ANTIPORTER; ARACHIDONIC ACID; CHELATING AGENT; CILOSTAMIDE; CILOSTAZOL; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; EPAC 1; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; INDOMETACIN; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; IONOMYCIN; MILRINONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHOLIPASE C; PHOSPHOLIPASE C EPSILON; PROSTACYCLIN; RAP1 PROTEIN; ROLIPRAM; TETRAACETOXYMETHYL ESTER; UNCLASSIFIED DRUG; ZAPRINAST; CALCIUM; GUANINE NUCLEOTIDE EXCHANGE FACTOR; PDE3B PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; RAPGEF3 PROTEIN, HUMAN; SMALL INTERFERING RNA; TELOMERE BINDING PROTEIN; TERF2IP PROTEIN, HUMAN; TETRAZOLE DERIVATIVE;

AORTA ENDOTHELIUM; ARTICLE; CALCIUM CELL LEVEL; CELL STIMULATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; PROSTAGLANDIN SYNTHESIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; AGONISTS; AORTA; BIOSYNTHESIS; CELL LINE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

AORTA; ARACHIDONIC ACID; CALCIUM; CELL LINE; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; ENDOTHELIAL CELLS; EPOPROSTENOL; GENE EXPRESSION REGULATION; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHODIESTERASE 3 INHIBITORS; PHOSPHOINOSITIDE PHOSPHOLIPASE C; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TELOMERE-BINDING PROTEINS; TETRAZOLES;

EID: 84941353440     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132835     Document Type: Article

References (30)

1. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F. Cilostazol as a unique antithrombotic agent. Curr Pharm Des. 2003; 9:2289-2302.
2. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) super family: A new target for the development of specific therapeutic agents. Pharmacol Ther. 2006; 109:366-398.
3. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, et al. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme. Biochem Pharmacol. 2000; 59:347-356.
4. Packer M. U.S. Department of Health and Human Services, Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee 85th Meeting. 1998; 1-491.
5. Porto I, D'Amario D, Crea F. Cilostazol and primary-PCI: mirage or good alternative? Curr Vasc Pharmacol. 2012; 10:468-471.
6. Sudano I, Spieker LE, Hermann F, Flammer A, Corti R, Noll G, et al. Protection of endothelial function: targets for nutritional and pharmacological interventions. J Cardiovasc Pharmacol. 2006; 47 Suppl 2: S136-S150.
7. Mitchell JA, Ali F, Bailey L, Moreno L, Harrington LS. Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp Physiol. 2008; 93(1):141-147.
8. Khazaei M, Moien-afshari F, Laher I. Vascular endothelial function in health and diseases Pathophysiology, 2008; 15 (1): 49-67.
9. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003; 23:168-175.
10. Manickavasagam S, Ye Y, Lin Y, Perez-Polo RJ, Huang MH, Lui CY, et al. The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther. 2007; 21:321-330.
11. Oyama N, Yagita Y, Kawamura M, Sugiyama Y, Terasaki Y, Omura-Matsuoka E, et al. Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats. Stroke. 2011; 42:2571-2577.
12. Sheu JJ, Lin KC, Tsai CY, Tsai TH, Leu S, Yen CH, et al. Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia. J Transl Med. 2012; 10:164.
13. Igawa T, Tani T, Chijiwa T, Shiragiku T, Shimidzu S, Kawamura K, et al. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res. 1990; 57:617-623.
14. Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ. cPLA2 is phosphorylated and activated by MAP kinase. Cell. 1993; 72:269-278.
15. Gloerich M, Bos JL. Epac: Defining a New Mechanism for cAMP Action. Annu Rev Pharmacol Toxicol. 2010; 50:355-375.
16. Zhang QH, Zu XY, Cao RX, Liu JH, Mo ZC, Zeng Y, et al. An involvement of SR-B1 mediated PI3K-AkteNOS signaling in HDL-induced cyclooxygenase 2 expression and prostacyclin production in endothelial cells. Biochem Biophys Res Commun. 2012; 420(1):17-23.
17. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F. Effect of anti-inflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999; 26(6):1366-1373.
18. Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol, 2007; 50: 470-479.
19. White DG, Martin W. Differential control and calcium dependence of production of endothelium-derived relaxing factor and prostacyclin by pig aortic endothelial cells. Br J Pharmacol. 1989; 97: 683-690.
20. Holz GG, Kang G, Harbeck M, Roe MW, Chepurny OG. Cell physiology of cAMP sensor Epac. J Physiol. 2006; 577.1:5-15.
21. Mayati A, Levoin N, Paris H, N'Diaye M, Courtois A, Uriac P, et al. Induction of intracellular calcium concentration by environmental benzo(a)pyrene involves a β2-adrenergic receptor/adenylyl cyclase/Epac- 1/inositol 1,4,5-trisphosphate pathway in endothelial cells. J Biol Chem. 2012; 287(6):4041-4052.
22. Qiu Z-H, Gijón MA, de Carvalho MS, Spencer DM, Leslie CC. The role of calcium and phosphorylation of cytosolic phospholipase A2 in regulating arachidonic acid release in macrophages. J Biol Chem. 1998; 273:8203-8211.
23. Nemenoff RA, Winitz S, Qian N-X, Van Putten V, Johnson GL, Heasley LE. Phosphorylation and activation of a high molecular weight form of phospholipase A2 by p42 microtubule-associated protein 2 kinase and protein kinase C. J Biol Chem. 1993; 268:1960-1964.
24. Wilson LS, Baillie GS, Pritchard LM, Umana B, Terrin A, Zaccolo M, et al. A phosphodiesterase 3Bbased signaling complex integrates exchange protein activated by cAMP 1 and phosphatidylinositol 3- kinase signals in human arterial endothelial cells. J Biol Chem. 2011; 286:16285-16296.
25. Hashimoto A, Miyakoda G, Hirose Y, Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis. 2006; 189:350-357
26. Brotherton AF, Macfarlane DE, Hoak JC. Prostacyclin biosynthesis in vascular endothelium is not inhibited by cyclic AMP. Studies with 3-isobutyl-1-methylxanthine and forskolin. Thromb Res. 1982; 28:637-647.
27. Cone J, Wang S, Tandon N, Fong M, Sun B, Sakurai K, et al. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol. 1999; 34(4):497-504.
28. Ray CJ, Abbas MR, Coney AM, Marshall JM. Interactions of adenosine, prostaglandins and nitric oxide in hypoxia-induced vasodilatation: in vivo and in vitro studies. J Physiol. 2002; 544 (1):195-209.
29. Ray CJ, Marshall JM. The cellular mechanisms by which adenosine evokes release of nitric oxide from rat aortic endothelium. J Physiol. 2006; 570 (1):85-96.
30. Parsons WJ, Ramkumar V, Stiles GL. The new cardiotonic agent sulmazole is an A1 adenosine receptor antagonist and functionally blocks the inhibitory regulator, Gi. Mol Pharmacol. 1988; 33(4):441-8.